Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
E
P 04
EARLY ON-TREATMENT CIRCULATING TUMOR DNA DYNAMICS TO PREDICT RESPONSE IN PATIENTS WITH SARCOMA
Favorite
P 103
EARLY OUTCOMES OF BONE PROSTHESIS COMPOSITE FOR RECONSTRUCTION IN LOWER LIMB TUMORS. A SINGLE INSTITUTION STUDY
Favorite
P 358
EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R), IN HEALTHY PARTICIPANTS
Favorite
P 376
EFFECT OF ITRACONAZOLE (ITZ) AND RABEPRAZOLE (RBP) ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR, IN HEALTHY PARTICIPANTS
Favorite
P 94
EFFECT OF POSTOPERATIVE PHYSICAL THERAPY ON FUNCTIONAL OUTCOMES FOLLOWING MUSCULOSKELETAL TUMOR RESECTION
Favorite
P 452
EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Favorite
P 32
EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Favorite
P 417
EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Favorite
P 413
EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Favorite
P 152
EFFICACY OF PALLIATIVE CHEMOTHERAPY AND LOCAL TREATMENTS IN ADVANCED CHONDROSARCOMA: A SUBTYPE-SPECIFIC RETROSPECTIVE ANALYSIS
Favorite
P 191
EFFICACY OF SYSTEMIC PALLIATIVE THERAPIES IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) PREVIOUSLY TREATED WITH ADJUVANT IMATINIB - REAL-WORLD CLINICAL PRACTICE DATA
Favorite
P 464
EFFICACY OUTCOMES AMONG PATIENTS WITH ADVANCED EPITHELIOID SARCOMAS OF PROXIMAL-TYPE AND DISTAL-TYPE TREATED WITH TAZ: POST HOC ANALYSIS OF STUDY EZH-202
Favorite
P 422
EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Favorite
P 253
ELUCIDATING THE ROLE OF SIRT7 IN EWING SARCOMA
Favorite
P 254
EOSINOPHILIC FASCIITIS (EF) AS A COMPLICATION OF NATURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY IN A YOUNG ADULT WITH RECURRENT METASTATIC EWING SARCOMA
Favorite
P 459
EPIDEMIOLOGICAL TRENDS, TREATMENT PATTERNS, AND SURVIVAL DISPARITIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A SEER ANALYSIS, 2001-2020
Favorite
P 70
EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF CONTACTIN-4 EXPRESSION IN SOFT TISSUE SARCOMA
Favorite
P 69
EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF TOP1 AND TOP2A TOPOISOMERASES EXPRESSION IN SOFT TISSUE SARCOMA
Favorite
P 395
ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Favorite
P 53
ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY
Favorite
P 09
ESTABLISHMENT AND CHARACTERIZATION OF 18 SARCOMA CELL LINES: UNRAVELING THE MOLECULAR MECHANISMS OF DOXORUBICIN RESISTANCE IN SARCOMA CELL LINES
Favorite
P 18
ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Favorite
P 11
ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Favorite
P 136
ESTROGEN HAS A PROTECTIVE EFFECT ON CHONDROSARCOMA GROWTH IN VITRO AND IN VIVO
Favorite
P 262
EVALUATING FRONT-LINE THERAPY ACCORDANCE WITH CURRENT SYNOVIAL SARCOMA GUIDELINES
Favorite
P 165
EVALUATING LARGE LANGUAGE MODELS AS DECISION SUPPORT TOOLS IN MULTIDISCIPLINARY TUMOR BOARDS FOR GASTROINTESTINAL STROMAL TUMORS
Favorite
P 63
EVALUATING SURGICAL MARGINS IN SARCOMA RESECTION WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Favorite
P 14
EVALUATING THE COMBINATION OF DISULFIRAM AND ENZALUTAMIDE IN OSTEOSARCOMA
Favorite
P 396
EVALUATING THE SAFETY AND EFFICACY OF METRONOMIC GEMCITABINE, DOXORUBICIN, AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA: A PHASE 2 STUDY (NCT04535713)
Favorite
P 323
EVALUATION OF COSMIC MUTATIONAL SIGNATURES IN SOFT TISSUE SARCOMA
Favorite
P 359
EVALUATION OF PREOPERATIVE MYXOFIBROSARCOMA GROWTH AND SURGICAL MORBIDITY AFTER NEOADJUVANT RADIATION USING SEMI-AUTOMATED VOLUMETRIC ANALYSIS
Favorite
P 47
EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Favorite
P 21
EXAMINING THE THERAPEUTIC EFFECT OF TBL1/ β-CATENIN TARGETED COMBINATION THERAPIES ON METASTATIC OSTEOSARCOMA
Favorite
P 236
EXCEPTIONAL RESPONSE TO COMBINATION IMMUNOTHERAPY WITH YH001 AND ENVAFOLIMAB IN METASTATIC SARCOMA.
Favorite
P 432
EXPANSION OF A PHASE 1 STUDY OF SON-1010 (IL12-FHAB) ADDING TRABECTEDIN IN SOFT TISSUE SARCOMA: TRIAL IN PROGRESS
Favorite
P 198
EXPLOITING METABOLIC DYSREGULATION IN SUCCINATE DEHYDROGENASE-DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Favorite
P 60
EXPLORING METABOLIC REWIRING IN CHORDOMA
Favorite
P 397
EXPLORING REAL WORLD DATA OF RECURRENCE IN NON-METASTATIC MYXOFIBROSAROMA: AN UPDATED RETROSPECTIVE COHORT STUDY
Favorite
P 135
EXPLORING THE ROLE OF CLUSTER OF DIFFERENTIATION 44 IN CHONDROSARCOMA
Favorite
P 34
EXPRESSION OF ONCOFETAL ANTIGEN 5T4 IN SARCOMA SUBTYPES AND PRECLINICAL ACTIVITY OF TUB-030, A NOVEL 5T4-TARGETING ANTIBODY-DRUG CONJUGATE (ADC)
Favorite
P 463
EXTRANODAL FOLLICULAR DENDRITIC CELL SARCOMAS AND THEIR OLIGORECURRENCES: TRIUMPHS, TRIALS AND LESSONS LEARNT AT A SINGLE TERTIARY CANCER REFERRAL CENTRE, INDIA.
Favorite
P 17
EXTRASKELETAL OSTEOSARCOMA: MICRORNA PATTERNS PROVIDE INSIGHTS INTO SIMILARITIES AND CONTRASTS WITH OTHER SARCOMAS
Favorite
P 15
EZHIP: A NOVEL EPIGENETIC DRIVER OF OSTEOSARCOMA PATHOGENESIS
Favorite
